Conference Coverage

AAN: Study supports safety of fingolimod for MS

Publish date: May 6, 2015

 

AT THE AAN 2015 ANNUAL MEETING

References

Dr. Cohen disclosed ties with Novartis, which funded the study.

emechcatie@frontlinemedcom.com

Pages

Recommended Reading

Alemtuzumab, two-course infusion, approved for relapsing MS
MDedge Family Medicine
Patient developed PML after taking Tecfidera
MDedge Family Medicine
FDA issues new pregnancy/lactation drug label standards
MDedge Family Medicine
Switch to oral fingolimod produces better MS outcomes
MDedge Family Medicine
‘No evidence of disease activity’ has potential as a useful outcome in MS
MDedge Family Medicine
New patient registry aims to become ‘Framingham’ of MS
MDedge Family Medicine
Interferon beta, glatiramer acetate prove effective for relapsing MS
MDedge Family Medicine
FDA approves first generic version of MS drug glatiramer acetate
MDedge Family Medicine
DECIDE: Daclizumab cuts MS relapse rate by 45%
MDedge Family Medicine
Peginterferon beta-1a MS data show positive early and long-term results
MDedge Family Medicine